MetaCap

Protagonist Therapeutics (PTGX) vs Rhythm Pharmaceuticals (RYTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protagonist Therapeutics (PTGX) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 42.2% versus a gain of 10.4%. Over five years, RYTM leads with a +1116.0% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.79 billion), about 1.0 times the size, while Rhythm Pharmaceuticals is growing revenue faster (+45.8% vs -89.4%).

Rhythm Pharmaceuticals converts more of its revenue into profit, with a net margin of -103.6% versus -282.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PTGX+42.15%RYTM+10.44%
+91%+30%-31%
Nov 21, 20251 yearNov 20, 2026
PTGX+246.56%RYTM+990.87%
+1078%+472%-134%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PTGX versus RYTM key metrics
MetricPTGXRYTM
Share price$121.40$112.36
Market cap$7.92B$7.79B
1-day change-2.11%-3.80%
YTD return+39.00%+4.97%
1-year return+42.15%+10.44%
5-year return+265.00%+1116.02%
P/E ratio (TTM)25.67—
Forward P/E348.79—
EPS (TTM)$4.73$-2.91
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$46.02M$189.76M
Revenue growth (YoY)-89.41%+45.83%
Net income (latest FY)$-130.15M$-196.54M
Gross margin—89.73%
Operating margin-343.63%-101.19%
Net margin-282.83%-103.57%
52-week high$160.81$122.20
52-week low$77.00$74.50
Distance from 52-week high-24.51%-8.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+50.21%+24.71%
Average volume668.45K1.10M
Shares outstanding65.27M69.33M
Employees149414
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PTGX has outperformed RYTM by 31.7 percentage points over the past year.
  • Rhythm Pharmaceuticals is more profitable, keeping -103.6 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
  • Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs -89.41%).

About Protagonist Therapeutics

PTGX stock →

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees

About Rhythm Pharmaceuticals

RYTM stock →

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees

PTGX vs RYTM FAQ

Which is bigger, Protagonist Therapeutics or Rhythm Pharmaceuticals?

Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).

Which stock has performed better over the past year, PTGX or RYTM?

PTGX returned +42.15% over the past 12 months, compared with +10.44% for RYTM (price return, excluding dividends). Past performance does not predict future results.

Are Protagonist Therapeutics and Rhythm Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons